Browse Articles

Filter By:

  • Effectiveness of one subcutaneous dose of MVA-BN, the smallpox and mpox vaccine, was estimated to be 86% in a cohort of vaccine-eligible males in Israel, supporting its use to curtail the outbreak of mpox virus.

    • Yael Wolff Sagy
    • Roy Zucker
    • Doron Netzer
    Article
  • In a phase I trial, the combination of dabrafenib, trametinib and spartalizumab uncovers the crosstalk between the MAPK pathway and the immune system, which offers a promising new strategy to improve clinical outcomes.

    • Elena Elez
    • Javier Ros
    • Josep Tabernero
    News & Views
  • Tumor mutation burden is an imperfect predictor of response to immunotherapies. Mutations in regions of the genome unlikely to undergo loss during tumor evolution constitute a persistent tumor mutation burden that may drive sustained immunological tumor control in the context of cancer immunotherapy.

    Research Briefing
  • Six supplements widely marketed as cholesterol-lowering agents performed poorly compared with a low-dose statin — with a similar safety profile.

    • Karen O’Leary
    Research Highlight
  • Despite concerns that bariatric surgery may increase patients’ risk of esophageal or gastric cancers, a large retrospective study offers reassurance that this is not the case.

    • Karen O’Leary
    Research Highlight
  • A large study finds that offering cash for vaccination does not have unintended negative consequences — providing much-needed data and alleviating some longstanding concerns.

    • Karen O’Leary
    Research Highlight
  • Patients with BRAFV600E-mutated colorectal cancer have encouraging overall response rates to inhibition of PD-1, BRAF and MEK, with translational analyses suggesting that induction of tumor-intrinsic programs and immune programs contributes to improved outcomes via MAPK inhibition.

    • Jun Tian
    • Jonathan H. Chen
    • Ryan B. Corcoran
    Article Open Access
  • Genomic analyses in large cohorts of patients with cancer identify a new measure of tumor mutational burden, based on genomic regions that are unlikely to undergo loss, that is associated with therapeutic response to immunotherapy.

    • Noushin Niknafs
    • Archana Balan
    • Valsamo Anagnostou
    Article Open Access
  • The US Food and Drug Administration should address health misinformation through existing and new regulatory approaches, including modernizing product labeling, investing in infodemic surveillance and addressing the roles of the internet and social media.

    • Kushal T. Kadakia
    • Adam L. Beckman
    • Harlan M. Krumholz
    Comment
  • We are launching a series on evidence in medicine, to discuss new approaches to assessing the safety and efficacy of cutting-edge health technologies and treatments.

    Editorial
  • Artificial intelligence algorithms have had mixed success in health, in part because regulation prevents them from evolving at the necessary rate.

    • David W. Bates
    World View
  • A study showing feasibility and preliminary efficacy of off-the-shelf CAR T cells represents steady progress on the long road to clinical use.

    • Jennifer N. Brudno
    • James N. Kochenderfer
    News & Views
  • A gene-therapy treatment applied to the skin resulted in dramatic wound healing in patients with epidermolysis bullosa, a painful and debilitating skin condition.

    • Karen O’Leary
    Research Highlight
  • We demonstrate the power of a data-informed medicines-based approach in discovering the indirect effect of the COVID-19 pandemic on cardiovascular events using 1.32 billion records of dispensed medications in England, Scotland and Wales. We estimate that interruption of preventive care could result in more than 13,000 extra cardiovascular events.

    Research Briefing